An independent peptide reference — no sellers, every claim sourced

Argireline

Also known as Acetyl hexapeptide-8, Acetyl hexapeptide-3, Ac-EEMQRR-NH2

Topical hexapeptide that inhibits SNARE complex formation and is said to soften expression lines.

early-clinical Skin & cosmetic cosmetic ingredient

At a glance

Category
Skin & cosmetic
Status
cosmetic ingredient
Route
topical, in a cream, serum or emulsion
Half-life
Not applicable with topical use; systemic absorption is negligible. The CIR panel notes a log P of -6.3, which makes percutaneous absorption unlikely 4, and a 2026 safety-evaluation framework measured 0.22% of an applied dose reaching the stratum corneum and 0.01% the viable epidermis 5
Onset
Studies measured effects after 4 to 12 weeks of daily use
Molecular weight
approximately 889 g/mol
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2

Registered as a cosmetic ingredient under the INCI name acetyl hexapeptide-8 (formerly acetyl hexapeptide-3); the amidated form used in cosmetics is acetyl hexapeptide-8 amide 4. It is not a medicine: cosmetics may not make pharmacological claims in the EU, and no medicines authority has assessed its efficacy. The only expert-panel review of the ingredient, by the US Cosmetic Ingredient Review, addresses safety and not efficacy: it concluded in 2025 that acetyl hexapeptide-8 amide is safe as currently used at concentrations up to 0.005%, and that the available data are insufficient to support safety above that level 4. It is applied exclusively topically in creams and serums, not injected.

Doping status: Not listed by WADA

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

Mechanism of action

Argireline mimics the N-terminal end of SNAP-25, one of the three proteins that make up the SNARE complex. By competing with the real SNAP-25 it is thought to destabilise the assembly of that complex and thereby inhibit the calcium-dependent vesicle fusion needed for acetylcholine release at the neuromuscular junction.

In theory, less acetylcholine release leads to less contraction of the facial muscles, and thus to shallower expression lines. The principle is loosely analogous to that of botulinum toxin, but the point of attack is different — botulinum toxin cleaves SNAP-25 enzymatically and is incomparably more potent in doing so.

The core of the debate lies not with the mechanism but with reachability. Argireline is a hydrophilic peptide of nearly 900 daltons with several charged groups; those are unfavourable properties for passage through the stratum corneum, and the CIR panel puts its log P at -6.3, which it treats as making percutaneous absorption unlikely 4. The one published measurement is stark: 0.22% of an applied dose reached the stratum corneum and 0.01% the viable epidermis 5 — the layer above the dermis, which is itself above the muscle. Whether it reaches the neuromuscular junction in a relevant concentration at all with topical application has not been established. Part of the measured effect is probably attributable to hydration and to the formulation base.

What the research shows

The evidence is limited and mixed. The original study came from the developers of the compound and was conducted in a small group; later independent evaluations are less positive. It is plausible that there is a small cosmetic effect, and implausible that it comes anywhere near injectable treatments.

Research in humans

In the original publication (Blanes-Mira et al., International Journal of Cosmetic Science, 2002) an oil-in-water emulsion containing 10% of the hexapeptide reduced wrinkle depth by up to approximately 30% after 30 days in a small group of healthy female volunteers 1. Later studies with twice-daily application over 4 weeks again showed improvement compared with placebo, but the strongest positive study was funded by the manufacturer and the original result has never been independently replicated. The most recent paper cited here is not a clinical evaluation at all: it is a longitudinal analysis of United States Google search volume for terms such as 'Argireline' and 'Botox in a bottle' from 2013 to 2023 3, which documents public interest in the ingredient rather than any effect of it — a distinction worth holding on to, given that interest is what the marketing generates.

Animal and lab research

In vitro research and experiments on isolated neuromuscular preparations confirm that the peptide can inhibit neurotransmitter release when delivered directly to the nerve endings. That says little about the situation after application to the skin.

Caveats. Small samples, short duration, predominantly manufacturer-funded research and no independent replication of the most-cited results. The measurement methods used (skin topography, expert assessment) are sensitive to expectation effects. The percentage in the studies moreover often refers to the commercial solution and not to pure peptide, which complicates comparison between studies and products. The most important open question — whether the compound reaches its target site — has never been resolved.

What it is used for

  • Topical care products aimed at fine lines and expression lines around the eyes and forehead
  • Often combined with matrixyl (palmitoyl pentapeptide-4) or SNAP-8 in the same formulation; acetyl hexapeptide-8 is among the three most-used peptides in marketed anti-ageing cosmetics 7
  • Presented as a non-invasive alternative to injectable treatments — a comparison the available data do not support. A 2026 systematic review of randomised trials of peptides in skin ageing found only two topical trials in the whole field, one of them the argireline study cited above 6

Dosing

Dose
Typically 5-10% of the commercial solution in the final formulation; this amounts to a considerably lower content of pure peptide
Frequency
Applied once to twice daily to clean skin
Route
topical — this is a cosmetic ingredient, not an injection peptide
Duration
4 to 12 weeks in studies; the effect disappears after stopping
  • This is emphatically not an injectable. No dosing protocol exists for subcutaneous or intradermal administration, and there is no research supporting it.
  • Product labels often state a percentage without specifying whether it refers to the commercial solution or the pure peptide. A product with '10% Argireline' usually contains far less than 10% peptide. The distinction is not academic: the CIR panel's safety conclusion covers use up to 0.005% of the pure ingredient and says the data are insufficient above that, which is roughly two thousand times lower than the headline number on the bottle 4.
  • The formulation matters: pH, penetration enhancers and the presence of an emulsion strongly influence absorption. An aqueous serum without further excipients probably performs less well than the emulsions used in the studies.
  • Argireline is not compatible with strongly acidic formulations and is therefore usually not used in the same product as high-concentration ascorbic acid.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Reconstitution

Vial sizes
Commercial form: aqueous solution of the peptide, usually in bottles for formulators; also available as loose powder
Solvent
water or an aqueous phase; not bacteriostatic water for injection — this ingredient is not reconstituted for injection
Storage
Store cool and dark; the commercial solution preferably at 2-8 °C. A preservative system is necessary in a finished product, because an aqueous peptide solution is microbiologically vulnerable.

Worked example

For a home-made formulation the commercial solution is usually added to the water phase at a temperature below 40 °C, up to 5-10% of the total weight, after which the pH is adjusted to approximately 5-6.

Add after the emulsion has cooled; heating above approximately 40 °C can damage the peptide. Avoid combination with strongly acidic or strongly alkaline phases.

Safety

Side effects

  • Generally well tolerated with topical use; cosmetic peptides as a class perform well in standard skin and eye irritation testing 5
  • Mild redness, tingling or itching at the site of application
  • Contact allergy is rare but has been described for peptide-containing formulations; peptides are typically not electrophilic and so lack the reactivity that drives delayed-type hypersensitivity 5, and more often the reaction is to preservatives or fragrance in the product
  • Eye irritation when applied too close to the eyelid margin

Do not use if

  • Known hypersensitivity to the ingredient or to the formulation
  • Damaged, inflamed or freshly treated skin (for example after a peel or laser treatment)
  • Do not apply to mucous membranes or in the eyes
  • Injecting this ingredient has never been studied and the commercial solutions are not sterile or pyrogen-free — that is a real risk factor, not a theoretical one
  • Pregnancy and breastfeeding: no specific research, although systemic exposure with topical use is negligible — topically applied cosmetic peptides are not expected to reach the bloodstream or lymphatic fluid 5

Interactions

With topical use no systemic drug interactions are to be expected, because a topically applied cosmetic peptide is not expected to reach the systemic circulation at all 5. Within a formulation the peptide is sensitive to extreme pH and to high concentrations of electrolytes. Concurrent use with retinoids or exfoliants can make the skin more sensitive and increase the chance of irritation.

Common questions

What is argireline?
Argireline (acetyl hexapeptide-8) is the original “Botox in a jar” cosmetic peptide — a topical ingredient that aims to soften expression lines by dampening the nerve signalling behind muscle contraction.
Does argireline actually work like Botox?
No. It is applied topically and is far milder than an injection of botulinum toxin; the measured effects on lines are modest and depend on the peptide actually penetrating the skin. It is a cosmetic ingredient, not a medical treatment.
What is the difference between argireline and SNAP-8?
SNAP-8 (acetyl octapeptide-3) is an extended version of argireline, marketed as longer and more effective; both aim at the same nerve-signalling step. See GHK-Cu vs SNAP-8.

Sources